by the government. Thus, treatment-policy adults who are either local residents who have recently visited the 'frontier' interior decisions made by public-health oYcers in endemic regions directly impact the clinical or residents of the interior who are visiting Georgetown. management of malaria in the vast majority of people infected.
In Guyana, the government abandoned chloroquine (CQ) as rst-line therapy against SUBJECTS AND METHODS P. falciparum in the early 1990s. Complaints of frequent therapeutic failure from doctors Study Site and Subjects A treatment trial was initiated in September prompted the decision to adopt the combination of quinine and pyrimethamine-1998 using the fever clinic at Georgetown Public Hospital in Georgetown, Guyana. sulfadoxine as rst-line therapy. Recommended quinine therapy requires three doses This clinic served as a referral centre for patients suspected of having malaria. The daily for 7 days. The drug causes ringing in the ears of most of those treated, as well as clinic typically processed 30-50 patients/ day, and 30%-50% of these usually proved vertigo and nausea. It is poorly tolerated and inadequate compliance with unsupervised slide-positive for P. falciparum or P. vivax malaria (with approximately twice as many therapy almost certainly occurs regularly. The risk of recurrent parasitaemia as a con-P. falciparum infections as P. vivax). Thick bloodsmears were stained with Giemsa and sequence of poor compliance with quinine must be weighed against that attributable screened, under oil immersion at ×1000, by Ministry of Health microscopists in the to resistance to CQ. Reliable data characterizing the therapeutic response to CQ clinic. Only patients with uncomplicated, slide-proven malaria were screened for enrollshould drive treatment-policy decisions on alternative therapeutic strategies. ment in the trial; those with severe or complicated malaria were referred for admission Phillips et al. (1996) described a P. vivax infection that had been acquired in Guyana to the hospital. Eligible volunteers were at least 5 years old and agreed to remain in the but failed to respond to CQ therapy. As this case was reported at a time when CQ vicinity of Georgetown during the 28 days of post-treatment follow-up. The requireremained the rst-line drug for P. vivax malaria in Guyana, it led to a review of the ment to remain available during follow-up caused the majority of the otherwise eligible national policy for the treatment of P. vivax and the present trial of the CQ treatment of subjects to decline to participate. Informed consent was provided in accordance with P. vivax. As no recent data from Guyana adequately described the therapeutic response U.S. Navy regulations governing the use of human subjects in medical research of local P. falciparum infections to CQ, such infections were also investigated. The treat-(SECNAVINST 3900.39B), and as approved by sanctioned committees for the protection ment policies for uncomplicated, P. falciparum and P. vivax malaria in Guyana, where malaria of human subjects at the Ministry of Health in Guyana, and the Naval Medical Research has become increasingly prevalent since the 1970s, were retrospectively evaluated. Center in Bethesda, Maryland. Subjects were examined by a physician and submitted The study was based in Georgetown, on the northern coast, where malaria was virtually to venipuncture for collection of 12-ml samples of whole blood. These samples were eradicated in the 1950s by spraying with DDT and the distribution of 'chloro-used for the cryopreservation of parasites, the nested PCR of small-subunit ribosomal quinized' salt (Giglioli, 1951; Giglioli et al., 1976) . Malaria on the northern coast remains RNA (ssrRNA) for con rmation of diagnosis (see below), and routine tests for de ciency in relatively rare (Rambajan, 1994) and virtually all the cases seen in Georgetown are in glucose-6-phosphate dehydrogenase (G6PD).
Con rmation of Screening Diagnosis
administered another 10 mg/kg in the subject's home or workplace. A nal dose, of The screening diagnoses based on the examination of Giemsa-stained thick bloodsmears 5 mg/kg, was likewise administered on the following day. were later checked in the laboratory using blood samples collected at enrollment. Con-HPLC was used to estimate CQ concentrations in whole-blood samples from subrmation included examination of Giemsastained thin bloodsmears (for all 49 subjects jects with suspected CQ-resistant P. vivax (Baird et al., 1997b) . enrolled) and a PCR-based assay for the 18srRNA gene (for the 30 samples identi ed under the microscope as positive for P. vivax). For the assay, DNA was extracted, from Follow-up Smears were prepared of blood samples blood samples spotted onto FTA ® gene cards (Life Technologies, Rockville, MD), collected from the subjects on each of days 0-6, 11, 14, 18, 21 and 28 (for those using a Chelex method (Kain and Lanar, 1991) . The DNA was then subjected to two infected with P. falciparum) or on days 0, 2, 4, 7, 11, 14, 18, 21 and 28 (for those rounds of PCR using the primers and amplication conditions described by Snounou infected with P. vivax). The level of any parasitaemia ( parasites/ml) was estimated by et al. (1993) . In brief, the rst round of PCR employed two Plasmodium-speci c primers counting parasites against 200 leucocytes, on the thick smear, and multiplying the count to amplify the DNA of any Plasmodium sp. present. In the second round, aliquots of by 40 (assuming each subject had 8000 leucocytes/ml). A member of the research product from the rst round were placed into four separate reaction vessels, each con-team visited each subject at his or her home or workplace to collect each post-enrollment taining species-speci c primers for unique 18srRNA sequences (Snounou et al., 1993) . sample and check on the subject's general health. Subjects complaining of illness were In a slight deviation from the published procedure, the rst and second rounds of PCR brought to the clinic for prompt evaluation by the physician on the research team. were run for 30 and 40 cycles, respectively. The assays were performed in a 96-well Subjects with slide-con rmed parasitaemia after day 3 received alternative therapy with format that included genomic DNA from P. falciparum and P. vivax (in distilled water) quinine and pyrimethamine-sulfadoxine.
For subjects without recurrent parasitaemia, as positive controls. Electrophoresis of each of the nested products of the second round follow-up ended on day 28. of PCR was performed in gels of either 3% NuSieve agarose (FMC BioProducts, Rockland, ME) or 2% SeaKem agarose Statistical Analysis Life tables were used to estimate the risks (FMC BioProducts). The gels were stained with ethidium bromide.
of CQ therapeutic failure for P. falciparum and P. vivax (Baird et al., 1997a) . Recurrent parasitaemia was taken as evidence of therapeutic failure, regardless of clinical signs and Treatment As part of the enrollment procedure on day 0, symptoms. Rescue therapy prompted by an inter-current parasitaemia (i.e. with a each subject was given uncoated tablets of chloroquine phosphate (ResochinTM ; Bayer, Plasmodium sp. diVerent to that observed on day 0) constituted a loss to follow-up. Mixed Leverkusen, Germany) in the clinic, at a dose 10 mg base/kg bodyweight. Each sub-infections contributed to the analysis of each species. The rationale for interpreting the ject was watched for 30 min after treatment and dosing was repeated if vomiting occurred. in-vivo test of CQ resistance in P. vivax was described by Baird et al. (1997a) . The next day a member of the research team RESULTS schizonts containing six to 14 merozoites each; variation in the sizes of the infected erythrocytes, from smaller to larger than Subjects Table 1 summarizes the demographic and normal; and bizarre, grossly enlarged erythrocytes (with diameters two or three times those parasitological characteristics of the study population. Overall, 49 subjects, all but nine of the uninfected erythrocytes), each containing a multinucleated form of the paraof them male, were enrolled. Although children were eligible, only one child (a girl site. For these infections, the PCR-based diagnosis of P. vivax was taken to be correct with P. falciparum) was enrolled. None of the subjects had G6PD de ciency. The for the purpose of reporting therapeutic responses to CQ, and the presentation of results of the thin-smear examinations and PCR-based assays indicated that, at enroll-results in this report re ects this approach.
Wherever discrepancies occurred between the ment, the subjects had pure infections with Plasmodium falciparum (14), P. vivax (13) thin-smear-based diagnosis and the results of the nested-PCR analysis, the latter were or P. malariae (one), or mixed infections either of P. falciparum and P. vivax (17) or assumed to be correct when estimating the risks of therapeutic failure. of P. falciparum, P. malariae and P. vivax (two).
Responses to Treatment Diagnosis Comparison of the results of subsequent Plasmodium falciparum
Six of the 33 subjects recorded as P. falciparum examinations of thick and thin bloodsmears and of the PCR-based assay with those of infections were lost to follow-up (i.e. they could not be located at home or work) prior the screening diagnosis demonstrated shortcomings in the initial thick-smear screen-to day 4, but all of the remaining 27 reached the end-point of recurrent parasitaemia or ing as the primary instrument of diagnosis (Table 2 ). In brief, many (62%) of the 26 day 28 of follow-up. Of these 27 subjects (see Table 3 ), four failed to clear their infections initially considered to be solely of P. vivax were found to be mixtures of P. falciparum parasitaemias by day 4 and were therefore given alternative treatment. P. vivax and P. falciparum. Five infections initially identi ed as solely of P. vivax and Another 11 subjects cleared their parasitaemias by day 4 but had to be given showing nested-PCR results consistent with P. vivax (or a mixture of P. vivax and alternative treatment because of recurrent P. falciparum parasitaemia by day 7 ( ve), P. falciparum) presented morphological characteristics considered incompatible with a between days 8 and 14 (four) or on days 17 (one) or 28 (one). Thirteen of the 27 submicroscopical diagnosis of P. vivax. These infections showed: pigmented trophozoites; jects diagnosed with P. falciparum did not have recurrent parasitaemia during the 28 days parasitaemias by day 4, >90% were free of all physical complaints except arthralgia and of follow-up. None of the 27 subjects with P. falciparum infection at enrollment developed dizziness by day 4. an inter-current P. vivax parasitaemia. The Figure illustrates the cumulative incidence of P. falciparum after the standard CQ therapy. Plasmodium vivax Three of the 32 subjects initially infected The risk of the therapeutic failure of CQ against P. falciparum in Guyana was esti-with P. vivax were lost to follow-up before day 4 (Table 3) . Another eight, all with mated at 33% by day 7 and 48% by day 14.
Of the subjects found to be infected with mixed infections at enrollment, were withdrawn because they had to be treated for P. falciparum at enrollment, >75% reported relief from physical complaints within 4 days recurrent P. falciparum parasitaemia by day 14.
Although two more subjects had (slide-and of their rst dose of CQ (Table 4) . Among those subjects who cleared their P. falciparum nested-PCR-con rmed) recurrent P. vivax * N is the number of subjects at risk in the interval, I the number of incident cases of therapeutic failure, w the number of withdrawals due to loss to follow-up or parasitaemia with another species, IR the interval risk {i/[N(w/2)]}, and CI is the cumulative incidence {1[(1IR a )×(1CI b )] } in which IR a is the current interval risk and CI b the cumulative incidence of the prior interval. † At enrollment. parasitaemia on day 14 or 28, each had DISCUSSION a whole-blood concentration of CQ plus desethyl-chloroquine on the day of recur-This report documents a substantial risk of therapeutic failure of CQ among a small rence (74 and 0 ng/ml) that was below the minimum eVective concentration for P. vivax. sample of subjects infected with P. falciparum in Guyana, South America. The sample only These two cases of recurrent parasitaemia were therefore considered consistent with represented a small proportion of the patients reporting to the enrollment site because CQ-sensitive P. vivax. most such patients had been infected in the incidence was 55%). Plasmodium falciparum in Guyana appears polarized with respect interior of the country while working for a living and wished to return to the interior as to CQ susceptibility, with resistant and susceptible populations mixed in roughly quickly as possible. That most of the subjects were adult males is probably evidence that equal proportions. Approximately one half of the infections recrudesced within 14 days, travel to (or residence in) the forested interior is a dominant risk factor for infection among whereas the other half appeared completely susceptible to CQ. This unusual pattern may patients seeking treatment in Georgetown; infection among populations resident in be a product of the termination, in the early 1990s, of the use of CQ as rst-line therapy the endemic interior occurs across all ages (Rambajan, 1994) . The present subjects against P. falciparum in Guyana, which presumably diminished the survival advantage represented people who had incidentally planned on remaining in Georgetown for at of resistance to the drug. In the absence of baseline data, however, this interpretation least 28 days, usually for reasons related to family activities. It seems unlikely that this represents just one of several possible explanations. produced a sample bias with respect to risk of therapeutic failure.
The small sample of P. vivax evaluated in this study failed to reveal any therapeutic Nearly half (48%) of the P. falciparum infections recurred within 14 days of the failure attributable to resistance to CQ.
Among the 32 subjects with P. vivax, only rst dose of CQ, with relatively few recurrences after day 14 (the 28-day cumulative two had recurrent P. vivax parasitaemia during 28 days follow-up, and both of these their recurrent parasitaemias). This nding corroborates similar observations in Africa had inadequate blood concentrations of CQ plus desethyl-chloroquine (<100 ng/ml) at and South-east Asia (HoVman et al., 1983; Khoromana et al., 1986) . However, CQ the time of the recurrence. If this sample were representative of P. vivax in Guyana, therapy in the face of even a relatively modest resistance has been associated with the risk of resistance to CQ would be less than one in 30 infections. Despite con-increased risk of malaria-attributable death (Zucker et al., 1996; Trape et al., 1998) . vincing evidence that CQ-resistant P. vivax occurs in Guyana (Phillips et al., 1996) , the The training of Ethiopian mothers to treat their young children with CQ reduced results of the present (albeit small-scale) study indicate that, during late 1998, the mortality in the children by 40% (Kidane and Morrow, 2000) . In this case, 'selfrisk of therapeutic failure because of such resistance was <5%.
treatment' with CQ was obviously better than no treatment, but eVective alternative The primary therapy currently recommended for uncomplicated, P. falciparum therapy would avoid the unnecessary risk of death resulting from parasitic resistance malaria in Guyana is 7 days of quinine and a single dose of pyrimethamine-sulfadoxine. to CQ. The 'self-treating' poor may not appreciate such risk after clinical recovery, This was the regimen provided to the present subjects who failed to clear their infections and they may fail to understand that CQ therapy may exacerbate the transmission with CQ. Unfortunately, many of these patients returned to the clinic within 2 weeks of malaria by creating asymptomatic but infectious carriers. An eVective alternative of their rst dose of quinine, all with recurrent P. falciparum parasitaemia (data therapy that costs as little as CQ but has an equally good safety and tolerance pro le not shown). As failure to comply with the unsupervised regimen of quinine was the rule would be required to undermine the economic forces that drive CQ use in the face among these subjects, this therapeutic strategy suVers obvious shortcomings. However, there of resistance.
The data shown in Table 2 demonstrate are few if any practical alternatives available to the local Ministry of Health. Neither the considerable inaccuracy in the initial screening diagnosis based on the examination government nor most residents of Guyana possess the economic wherewithal to pur-of thick bloodsmears. Given the high risk of CQ-resistant P. falciparum and the conchase highly eVective and well-tolerated antimalarials such as Lariam ® (me oquine) tinued use of CQ as the rst-line treatment for P. vivax infection in Guyana, the large or Malarone ® (atovaquone-proguanil). Therapies involving artemisinin derivatives proportion of mixed P. vivax/P. falciparum infections misdiagnosed as pure P. vivax are not available. Uncomplicated, P. falciparum malaria in Guyana appears to receive infections (62%) is worrisome. Many individuals infected with P. falciparum must be inadequate therapy often.
Despite the high risk of parasitological receiving only CQ therapy on the basis of a P. vivax diagnosis at screening. The clinic failure with CQ against P. falciparum, most subjects infected with this parasite experi-where this study was conducted employed two or three, full-time microscopists who enced almost complete clinical recovery within 4 days of their rst dose of the drug (Table 4) . essentially worked non-stop during the hours of the clinic's operation, to keep up with This was especially true among those who managed to clear their parasitaemias by the demand. The addition of thin-smear reading, to increase the chances of detecting day 4. Most experienced rapid and substantial relief from illness despite the high P. falciparum in mixed infections, would very substantially increase the workload and, like risk of recurrence with symptoms (13 of 15 complained of being ill at the time of PCR-based assays, would not be practical with the available resources. The solution ment of CQ as the rst-line drug for such
